Affordable Access

deepdyve-link
Publisher Website

Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.

Authors
  • Kropeit, Dirk1
  • McCormick, David2
  • Erb-Zohar, Katharina3
  • Moiseev, Valentin S4
  • Kobalava, Zhanna D5
  • Stobernack, Hans-Peter1
  • Zimmermann, Holger1
  • Rübsamen-Schaeff, Helga1
  • 1 AiCuris Anti-infective Cures GmbH, Wuppertal, Germany. , (Germany)
  • 2 DMPK Solutions Limited, Nottingham, UK.
  • 3 Clinphase, Hanau, Germany. , (Germany)
  • 4 Centre for Applied Clinical Pharmacology, Clinical Hospital #3, GOUVPO Russian Peoples' Friendship University, Moscow, Russia.
  • 5 Centre for Applied Clinical Pharmacology, City Clinical Hospital #64, GOUVPO Russian Peoples' Friendship University, Moscow, Russia.
Type
Published Article
Journal
British Journal of Clinical Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Dec 01, 2017
Volume
83
Issue
12
Pages
2678–2686
Identifiers
DOI: 10.1111/bcp.13376
PMID: 28722153
Source
Medline
Keywords
License
Unknown

Abstract

Moderate hepatic impairment increased exposure to letermovir <2-fold, while severe hepatic impairment increased letermovir exposure approximately 4-fold as compared with healthy subjects. Letermovir 60/30 mg/day was generally well-tolerated in subjects with hepatic impairment.

Report this publication

Statistics

Seen <100 times